Home > Boards > US Listed > Biotechs >

Enanta Pharmaceuticals (ENTA)

ENTA RSS Feed
Add ENTA Price Alert      Hide Sticky   Hide Intro
Moderator: DewDiligence
Search This Board: 
Last Post: 4/12/2019 9:55:46 AM - Followers: 68 - Board type: Free - Posts Today: 0
ENTA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTA News: Enanta Pharmaceuticals Presents New Preclinical Data on Compounds Targeting Hepatitis B Virus & Non-Alcoholic Steatohepatitis... 04/11/2019 10:13:00 AM
ENTA News: Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2019 03/27/2019 05:24:00 AM
ENTA News: Enanta Pharmaceuticals Completes Enrollment in Two Ongoing Phase 2 Studies 03/18/2019 07:30:00 AM
ENTA News: Statement of Changes in Beneficial Ownership (4) 03/12/2019 04:53:09 PM
ENTA News: Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences 03/11/2019 07:30:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#1738  Sticky Note ENTA FY1Q19 results—GAAP EPS=$1.25: DewDiligence 02/06/19 04:07:28 PM
#1755   ABBV's Mavyret weekly NRx market share of the guyschmid 04/12/19 09:55:46 AM
#1754   ENTA’s EASL presentations (NASH, HBV): DewDiligence 04/11/19 10:18:23 AM
#1753   ABBV's Mavyret weekly NRx market share of the guyschmid 04/05/19 08:47:34 AM
#1752   ABBV's Mavyret weekly NRx market share of the guyschmid 03/29/19 11:05:43 AM
#1751   ENTA’s EASL lineup: DewDiligence 03/27/19 09:05:57 AM
#1750   ABBV's Mavyret weekly NRx market share of the guyschmid 03/25/19 09:26:24 AM
#1749   JNJ formally abandons RSV program: #msg-147714156. DewDiligence 03/21/19 06:26:06 PM
#1748   https://twitter.com/DewDiligence/status/1108727744999931904 DewDiligence 03/21/19 09:54:22 AM
#1747   New corporate slide set: DewDiligence 03/18/19 02:58:17 PM
#1746   ENTA completes enrollment in phase-2 NASH and RSV trials: DewDiligence 03/18/19 09:17:43 AM
#1745   ABBV's Mavyret weekly NRx market share of the guyschmid 03/08/19 10:01:01 AM
#1744   Highest close ($105.66) since Jul 2018. DewDiligence 03/01/19 04:14:59 PM
#1743   ABBV's Mavyret weekly NRx market share of the guyschmid 03/01/19 12:19:48 PM
#1742   ABBV's Mavyret weekly NRx market share of the guyschmid 02/22/19 08:38:57 AM
#1741   ENTA FY1Q19 CC transcript: DewDiligence 02/11/19 09:34:56 AM
#1740   Additional details on Mavyret’s US scripts for week DewDiligence 02/08/19 11:23:31 AM
#1739   ABBV's Mavyret weekly NRx market share of the guyschmid 02/08/19 08:45:18 AM
#1738   ENTA FY1Q19 results—GAAP EPS=$1.25: DewDiligence 02/06/19 04:07:28 PM
#1737   ABBV/ENTA had a 54%* worldwide share of 4Q18 DewDiligence 02/04/19 04:28:57 PM
#1736   ABBV's Mavyret weekly NRx market share of the guyschmid 02/01/19 09:26:54 AM
#1735   ABBV 4Q18 HCV sales=$862M—flat vs 3Q18: DewDiligence 01/25/19 07:57:21 AM
#1734   ENTA’s General Counsel exercised and held ~$150K of DewDiligence 01/24/19 07:16:21 PM
#1733   The annual-meeting proxy has been filed: DewDiligence 01/18/19 04:35:33 PM
#1732   ENTA CEO is a 5% shareholder (as of 12/20/18): DewDiligence 01/18/19 04:20:17 PM
#1731   ABBV's Mavyret weekly NRx market share of the guyschmid 01/18/19 09:37:18 AM
#1730   New corporate slide set: DewDiligence 01/07/19 03:18:56 PM
#1729   ENTA enumerates clinical goals for 2019—discussion during today’s DewDiligence 01/07/19 09:43:18 AM
#1728   ABBV's Mavyret weekly NRx market share of the guyschmid 01/04/19 09:57:26 AM
#1727   ENTA’s phase-2a RSV trial started recruiting 10/17/18: DewDiligence 01/01/19 11:12:16 AM
#1726   I don't have the weekly scripts yet—will post DewDiligence 12/21/18 07:42:24 PM
#1725   Any news last Friday and this week on JK2016 12/21/18 07:15:38 PM
#1724   That's the highest-ever weekly figure, according to IMS. DewDiligence 12/07/18 10:29:36 AM
#1723   ABBV's Mavyret weekly NRx market share of the guyschmid 12/07/18 09:17:56 AM
#1722   ENTA’s General Counsel exercised and held $150K of DewDiligence 12/06/18 08:52:27 PM
#1721   ENTA SVP exercised and held $150K of stock yesterday: DewDiligence 12/04/18 07:56:35 PM
#1720   ABBV's Mavyret weekly NRx market share of the guyschmid 11/30/18 08:41:39 AM
#1719   ENTA’s enterprise value at current share price ~$1.44B: #msg-145176914. DewDiligence 11/29/18 05:09:56 PM
#1718   ENTA FY4Q18 CC transcript: DewDiligence 11/27/18 09:17:16 AM
#1717   ENTA FY4Q18 results—GAAP EPS=$1.30: DewDiligence 11/26/18 04:08:15 PM
#1716   ENTA’s latest corporate slides: DewDiligence 11/25/18 07:17:16 PM
#1715   ABBV's Mavyret weekly NRx market share of the guyschmid 11/16/18 08:39:11 AM
#1714   Mavyret data from AASLD: DewDiligence 11/13/18 12:17:54 PM
#1713   ABBV's Mavyret weekly NRx market share of the guyschmid 11/09/18 08:41:04 AM
#1712   ABBV's Mavyret weekly NRx market share of the guyschmid 11/02/18 08:59:57 AM
#1711   ABBV 3Q18 results—HCV sales=$862M (vs ABBV’s $850M guidance): DewDiligence 11/02/18 08:14:23 AM
#1710   ABBV's Mavyret weekly NRx market share of the guyschmid 10/26/18 09:11:45 AM
#1709   EDP-938 (RSV) update on phase-1/phase-2 trials: DewDiligence 10/23/18 10:48:30 AM
#1708   ABBV's Mavyret weekly NRx market share of the guyschmid 10/19/18 09:28:07 AM
#1707   From the Japanese drug email list - Rocky3 10/14/18 10:44:33 PM
#1706   Mavyret’s US new-patient share=53.4%—the highest-ever weekly figure—in th DewDiligence 10/12/18 09:09:48 AM
PostSubject